A Phase 4 interventional study of Sarecycline and Doxycycline in Acne Vulgaris, sponsored by Integrative Skin Science and Research. Recruiting at 1 site in United States. Open to participants aged 9 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Integrative Skin Science and Research · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.
Among the 12 studies testing doxycycline in Acne Vulgaris, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 4, and was the 12th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Sites in Bangladesh
Ages 18+
By country, each count listing its studies:
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 2 · Phase 4 6
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 47 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 10 most frequent:
Integrative Skin Science and Research is the lead sponsor of 35 studies on the registry; 12 are open to participants now.
Integrative Skin Science and Research has 9 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
2 of the studies testing doxycycline in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07544251Integrative Skin Science and ResearchComparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne. | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to help better understand how the gut and skin bacteria of the body change when people with acne are treated with Sarecycline or Doxycycline. The bacteria in the gut and on the skin will be studied to see how each treatment may affect them and whether they change the profile of the bacteria that is present.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Diagnosis of acne vulgaris with:
Exclusion Criteria:
2a) Within 2 week prior to randomization:
Topical anti-inflammatories and
2b) Within 4 weeks prior to randomization:
Systemic corticosteroids
2c) Within 12 weeks prior to randomization:
Systemic retinoids
3) Individuals who have changed any of their hormonal based or therapies within 3 months prior to joining the study.
4) Individuals who are pregnant or breastfeeding.
5) Individuals on oral contraceptive pills or progesterone or estrogen containing therapies unless they have been on a stable dose for 2 months.
6) Individuals on finasteride or dutasteride
7) Current tobacco smoker or a tobacco smoking history that is greater than 5 pack-years.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Half of the participants will be randomized to receive sarecycline treatment.
Drug: Sarecycline
Half of the participants will be randomized to receive doxycycline treatment.
Drug: Doxycycline
One tablet by mouth (weight based dosing at 1.5 mg/kg and rounded to the closest tablet dose at either 60 mg, 100mg, or 150 mg tablet) once a day with food and a full glass of water (about 8 ounces)
100 mg twice daily with food and a full glass of water (about 8 ounces)
Change in the relative abundance of tetracycline-resistant bacteria in the gut microbiome
Assessing change in the relative abundance of tetracycline resistant bacteria in the gut microbiome following treatment.
Time frame: From enrollment to the end of treatment at 4 weeks.
Change in the relative abundance of fungi/yeast in the gut microbiome
Assessing change in the relative abundance of fungi/yeast in the gut microbiome following treatment.
Time frame: From enrollment to the end of treatment at 4 weeks.
Change in inflammatory and non-inflammatory lesions
Assesing change in inflammatory and non-inflammatory lesions.
Time frame: From enrollment to the end of treatment at 4 weeks.
Change in the diversity of the gut microbiome: Shannon Diversity
Assessing the change in Alpha Diversity of the gut microbiome via Shannon Diversity
Time frame: From enrollment to the end of treatment at 4 weeks.
Change in investigator global assessment of acne
Change in investigator global assessment of acne
Time frame: From enrollment to the end of treatment at 4 weeks.
Change in relative abundance of short chain fatty acid production genes
Assessing change in relative abundance of short chain fatty acid production genes upon gut microbiome analysis.
Time frame: From enrollment to the end of treatment at 4 weeks.
Change in skin microbiome relative abundance
Assessing change in the relative abundance of the skin microbiome via Shannon Diversity.
Time frame: From enrollment to the end of treatment at 8 weeks.
Change in the skin microbiome relative abundance of fungi/yeast
Assessing change in the relative abundance of fungi/yeast in the skin microbiome.
Time frame: From enrollement to the end of treatment at 4 weeks.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.
Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 12 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sarecycline · Doxycycline
Integrative Skin Science and Research →